Ilypsa, Inc. Completes Enrollment of Phase 2 Clinical Trial of ILY101 For Patients With Chronic Kidney Disease On Hemodialysis
2/6/2007 11:48:40 AM
SANTA CLARA, Calif.--(BUSINESS WIRE)--Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal disorders, announced today that it has completed enrollment of the company’s Phase 2 clinical trial of ILY101 in the United States. ILY101 is a novel phosphate binding agent for the treatment of hyperphosphatemia, a serious complication in patients with kidney disease on dialysis.
comments powered by